Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer

Chi Kang Lin, Meng Yi Bai, Teh Min Hu, Yu Chi Wang, Tai Kuang Chao, Shao Ju Weng, Rui Lan Huang, Po Hsuan Su, Hung Cheng Lai

研究成果: 雜誌貢獻文章同行評審

39 引文 斯高帕斯(Scopus)

摘要

Ovarian cancer treatment remains a challenge and targeting cancer stem cells presents a promising strategy. Niclosamide is an "old" antihelminthic drug that uncouples mitochondria of intestinal parasites. Although recent studies demonstrated that niclosamide could be a potential anticancer agent, its poor water solubility needs to be overcome before further preclinical and clinical investigations can be conducted. Therefore, we evaluated a novel nanosuspension of niclosamide (nano-NI) for its effect against ovarian cancer. Nano-NI effectively inhibited the growth of ovarian cancer cells in which it induced a metabolic shift to glycolysis at a concentration of less than 3 μM in vitro and suppressed tumor growth without obvious toxicity at an oral dose of 100 mg/kg in vivo. In a pharmacokinetic study after oral administration, nano-NI showed rapid absorption (reaching the maximum plasma concentration within 5 min) and improved the bioavailability (the estimated bioavailability for oral nano-NI was 25%). In conclusion, nano-NI has the potential to be a new treatment modality for ovarian cancer and, therefore, further clinical trials are warranted.
原文英語
頁(從 - 到)8993-9006
頁數14
期刊Oncotarget
7
發行號8
DOIs
出版狀態已發佈 - 2016

ASJC Scopus subject areas

  • 腫瘤科

指紋

深入研究「Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer」主題。共同形成了獨特的指紋。

引用此